SACUVAL 50MG/100MG/200MG

The essential treatment for heart failure with reduced EF (ICFEr)

SACUVAL is indicated to reduce the risk of cardiovascular mortality and morbidity in adult patients with systolic heart failure (NYHA class II-IV, LVEF ≤ 40%). SACUVAL is administered in appropriate combination with other heart failure treatments (e.g., beta blockers, diuretics, and mineralocorticoid receptor antagonists) instead of an IEC or an ARB II.